SENSEX NIFTY
YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > News - Ranbaxy Laboratories
Ranbaxy Laboratories
BSE: 500359|NSE: RANBAXY|ISIN: INE015A01028|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Dec 19, 16:30
617.45
-3.1 (-0.5%)
VOLUME 45,990
LIVE
NSE
Dec 19, 16:30
617.95
-2.3 (-0.37%)
VOLUME 665,598
Business News on Ranbaxy Laboratories
Select Year: 2013 |  2012 |  2011 | 2010 | 2009 | 2008 | 2007 | 2000-2006
Approval for Ranbaxy to launch Synriam in 7 African nations

3.31 pm | 15 Dec 2014 |  Source: PTI

The company has received regulatory approval to launch its first New Chemical Entity (NCE) Synriam in seven African countries -- Nigeria, Uganda, Sene...

Ranbaxy gets nod to launch Synriam in 7 African countries

2.52 pm | 15 Dec 2014 |  Source: PTI

Drug firm Ranbaxy Laboratories has received regulatory nod to launch its indigenously developed anti-malarial drug Synriam in 7 African nations....

Sun-Ranbaxy: Agency to monitor drug divestment, says CCI 

10.59 am | 09 Dec 2014 |  Source: CNBC-TV18

In an interview to CNBC-TV18, Ashok Chawla, Chairperson, CCI, said the order on Sun-Ranbaxy merger is final and that the companies could be given addi...

AstraZeneca, Ranbaxy prevail in Nexium antitrust trial

2.14 pm | 06 Dec 2014 |  Source: Reuters

The US Federal Trade Commission estimates that pay-for-delay deals, in which a branded drugmaker pays a generic rival to stay off the market, cost con...

EU bans imports from Ranbaxy's antibiotic injectables unit

8.32 pm | 04 Dec 2014 |  Source: Reuters

European authorities inspected all units at Ranbaxy's Dewas plant, in Madhya Pradesh, in June and did not approve the manufacturing practices at the u...

Ranbaxy launches arthritis drug Infimab in India

4.20 pm | 01 Dec 2014 |  Source: PTI

Remicade is currently marketed for the treatment of inflammatory diseases including rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, ulc...

Reviewing M&A deals not a 'crystal gazing': CCI chief

2.32 pm | 01 Dec 2014 |  Source: PTI

CCI chairman Ashok Chawla's comments come at a time when some of the major M&As, including the USD 4 billion Sun Pharma-Ranbaxy transaction, have been...

US court refuses Ranbaxy plea to block ANDA nod for 2 drugs

2.34 pm | 26 Nov 2014 |  Source: PTI

Ranbaxy Laboratories had sued USFDA over revoking an approval to sell generic versions of Nexium and Valcyte in the US market....

CCI begins public scrutiny of Holcim-Lafarge deal

2.25 pm | 22 Nov 2014 |  Source: PTI

The comments with respect to the Holcim-Lafarge deal need to be submitted to the CCI (Competition Commission of India) within 15 days, along with supp...

Ranbaxy sues FDA for revoking approvals for Nexium, Valcyte

2.55 pm | 18 Nov 2014 |  Source: Reuters

In the suit filed in the District Court for the District of Columbia, Ranbaxy said the FDA's move violated constitutional rights, exceeded the agency'...

Quick Links for Ranbaxy Laboratories
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.